問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Radiation Therapy

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間：2025-11-06

曾政森TSENG, JENG-SEN
  • Principal Investigator
  • Clinical Trial Experience (year)

  • tzeng64@gmail.com

Recruiting Trial

118Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

曾政森

List

205Cases

2017-08-24 - 2020-12-31

Phase III

A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)

  • Condition/Disease

    Small Cell Lung Cancer (SCLC)

  • Test Drug

    Rovalpituzumab Tesirine(Rova-T)

Participate Sites
4Sites

Terminated4Sites

2012-09-01 - 2016-09-01

Phase II

A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects with Brain Metastases from Non-Small Cell Lung Cancer

  • Condition/Disease

    Brain Metastases from Non-Small Cell Lung Cancer

  • Test Drug

    ABT-888 (Veliparib)

Participate Sites
6Sites

Terminated6Sites

2019-04-01 - 2022-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting1Sites

Terminated7Sites

2019-04-01 - 2022-12-31

Phase II

A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs)

  • Condition/Disease

    non-squamous non-small cell lung cancer

  • Test Drug

    Durvalumab、Tremelimumab

Participate Sites
8Sites

Recruiting8Sites

夏德椿
China Medical University Hospital

Division of General Internal Medicine

2019-09-01 - 2019-08-06

Phase III

Regarding tislelizumab (BGB-A317) combined with chemotherapy and radiotherapy followed by tislelizumab monotherapy for use in newly diagnosed, locally advanced, unresectable stage III non-small cell lung cancer subjects for a phase 3, random assignment, double blind, Placebo controlled trial.

  • Condition/Disease

    NSCLC

  • Test Drug

    Tislelizumab

Participate Sites
8Sites

Recruiting3Sites

Terminated5Sites

2014-05-01 - 2017-04-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2016-09-12 - 2019-12-05

Phase III

Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    MYL-1402O

Participate Sites
6Sites

Terminated6Sites

2013-02-01 - 2018-06-30

Phase III

A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX/011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

  • Condition/Disease

    Advanced or metastatic (Stage IV) non-small cell lung cancer (NSCLC)

  • Test Drug

    Custirsen

Participate Sites
6Sites

Terminated6Sites

2015-07-01 - 2019-12-16

Phase III

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Atezolizumab (MPDL3280A)

Participate Sites
12Sites

Terminated12Sites

2015-07-01 - 2019-12-16

Phase III

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel Or MPDL3280A In Combination With Carboplatin + Nab-Paclitaxel Versus Carboplatin + Nab-Paclitaxel In Chemotherapy-Naïve Patients With Stage IV Squamous Non-Small Cell Lung Cancer

  • Condition/Disease

    Squamous Non-Small Cell Lung Cancer

  • Test Drug

    MPDL3280A

Participate Sites
13Sites

Terminated13Sites

1 14 15 16 17 18 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB